Abstract: Compounds useful for treating hepatitis C virus infection. The compounds are of formula (I): wherein A, B, C, D, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, m, n, p, q, r, t, u, and v are defined herein. Also disclosed is a method for treating hepatitis C virus infection with these compounds.
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, and X are defined herein. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.
Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.
Abstract: Methods for identifying a therapeutic agent for treating a Germinal Center Kinase (GCK)-Like Kinase (GLK)-mediated disease are disclosed. Methods for detecting a modulation of GLK signaling by a lest compound are disclosed. Also disclosed are methods for detecting the presence and/or severity of an autoimmune disease and/or cancer.
Abstract: Imidazol-4-one or imidazole-4-thione compounds of formula (I): wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.
Abstract: A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising H2O; (ii) an oil phase comprising oil dispersed in the continuous aqueous phase, comprising an internal aqueous phase comprising H2O, being dispersed in the oil phase; and a physiologically acceptable lipophilic emulsifier selected from the group consisting of mannide monooleate and sorbitan esters, stabilizing the interface between the inner aqueous phase and the oil phase to form a water-in-oil (W/O) emulsion; and (iii) poly(ethylene glycol)-block-poly(lactide-co-?-caprolactone), stabilizing the interface between the oil phase and the continuous aqueous phase.
Abstract: A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is encapsulated within the first polymeric particle; and (c) a third composition comprising a third bioactive agent, encapsulated within either the first or the second polymeric particle, wherein the second composition is released subsequently to the release of the first composition, and wherein the first bioactive agent is a neurotrophic factor, the second bioactive agent is a collagen synthesis inhibitor, and the third bioactive agent is selected from the group consisting of cyclic AMP (cAMP), an adenylate cyclase activator and a Rho inhibitor.
Type:
Grant
Filed:
August 27, 2009
Date of Patent:
December 18, 2012
Assignee:
National Health Research Institutes
Inventors:
Yu-Chao Wang, Yi-Ting Wu, Chung-Shi Yang
Abstract: Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo.
Abstract: Methods of preparing a composition comprising non-ionic, radioactive gold nanoparticles (R-GNPs) are disclosed. The method comprises: a) providing an aqueous composition comprising gold (Au-197) ions in the absence of a template; and b) exposing the aqueous composition in the absence of the template to neutron irradiation to generate the composition comprising the non-ionic R-GNPs. Alternatively, the method comprises: a) providing an aqueous composition comprising gold (Au-197) nanoparticles (GNPs) in the absence of a template; and b) exposing the aqueous composition comprising the GNPs in the absence of the template to neutron irradiation and thereby generating the composition comprising the non-ionic R-GNPs. Compositions that comprises mesoporous silica nanoparticles (MSNs) and non-ionic R-GNPs encapsulated within pores and/or channels and further anchored to the surfaces of the MSNs, and methods of making the same are also disclosed.
Type:
Grant
Filed:
December 14, 2009
Date of Patent:
November 13, 2012
Assignees:
National Health Research Institutes, National Tsing Hua University
Abstract: This invention provides combinations of novel oligonucleotides and their use in detecting a deletion(s) in the Pre-S region of HBV. Such a deletion(s) is associated with an increased risk of developing cirrhosis or hepatocellular carcinoma.
Type:
Grant
Filed:
June 9, 2009
Date of Patent:
October 23, 2012
Assignee:
National Health Research Institutes
Inventors:
Wenya Huang, Ih-Jen Su, Fang-Ching Shen
Abstract: A medical system and method for treating a disorder of a subject by thermal ablation, e.g., focused ultrasound thermal ablation, are provided. The method includes obtaining medical images that include at least one image of subject's chest and ribs to reconstruct a three-dimensional chest-rib distribution; and applying ultrasound waves on a target point beyond the subject's ribs by selectively activating one or more elements of an ultrasound phased array to avoid ultrasonic energy absorption or reflection by an intervening rib based on a calculation of a relationship between the three-dimensional chest-rib distribution and an acoustic emission direction.
Abstract: A compound of formula (I): wherein A, B, D, X, Y, R1, R2, R3, m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.
Abstract: A method of synthesizing a random copolymer of polyethyleneimine and polyethylene glycol, comprising exposing ethanolamine in a solution to electromagnetic radiation for a sufficient time to polymerize the ethanolamine (OHCH2CH2NH2) and thereby resulting in formation of the randome copolymer comprising polyethyleneimine and poly(ethylene glycol), wherein the polyethyleneimine comprises ethyleneimine (—CH2CH2NH—) unit and the polyethylene glycol comprises ethylene glycol (—CH2CH2O—) unit, and the polyethylenimine of the random copolymer has a substantially linear backbone.
Abstract: A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.
Abstract: The present invention describes a recombinant construct for detection of halogenated aromatic hydrocarbon compounds. A method for detecting halogenated aromatic hydrocarbon compounds using the recombinant construct is also described.
Abstract: A transgenic mouse expressing JSRV Env transgene that is operably linked to a surfactant protein C promoter (SPCp) is disclosed. The transgenic mouse is prone to developing a lung tumor and serves as an animal model for human lung carcinoma.
Abstract: A blood flow control system, tension adjustable instrument and a method are disclosed. The blood flow control system comprises a detecting unit, a computing and a tension adjustable instrument. The detecting unit real-time monitors the biomolecular response condition of a living organ, and the computing unit dynamically controls the tension adjustable instrument to adjust the tension of the blood vessel based on the detecting result. Therefore the blood flow control system can maintain the biomolecular response condition over a predetermined range to reduce the risk of the liver organ being damaged and augment the curability.
Abstract: In one aspect, in general, a method is provided for detecting temperature and protein denaturation of a tissue during thermal therapy. The method includes generating a plurality of MR pulse sequences that include a first group of pulse sequences and a second group of pulse sequences, and receiving a plurality of response signals that include a first and second group of response signals in response to the first and second groups of pulse sequences, respectively. A first information associated with a degree of protein denaturation of the tissue is determined based on the first and second groups of response signals. A second information associated with a temperature of the tissue is determined based on at least some of the plurality of response signals.
Type:
Grant
Filed:
May 5, 2008
Date of Patent:
July 24, 2012
Assignee:
National Health Research Institutes
Inventors:
Wen-Yih Isaac Tseng, Hsu-Hsia Peng, Teng-Yi Huang, Hsiao-Wen Chung